Breaking Into Wall Street – Venture Capital & Growth Equity Modeling 2024

Sale Page: https://breakingintowallstreet.com/venture-capital-modeling/

👉 Check All Exclusive Courses HERE 👈

Proof Download

Breaking Into Wall Street – Venture Capital & Growth Equity Modeling 2024

How to Master Cap Tables, Startup Valuation, and Exit Modeling – So You Can Ace Your Venture Capital

and Growth Equity Interviews and Advance to the Top

Our approach focuses on the 3 most important points in venture capital and growth equity interviews:

The Numbers

You need to know the cap table math and financial analysis around a company’s growth

and potential exit, so each case study here covers that.

The Market

But it’s equally important to understand the market, including why a company’s product might succeed or fail,

its pricing and potential sales, and how it differentiates itself from competitors.

The Recommendation

Finally, you need to understand how to put together all the pieces to make an investment recommendation.

You must be able to look at a company and its financial, product, and market information and say “Yes” or “No.”

Through Venture Capital & Growth Equity Modeling 2024, you’ll learn to:

Analyze a startup’s market and customers, including cohort analysis for Software as a Service (SaaS) companies.

Build capitalization tables (cap tables) for Seed and Series A – C funding rounds.

Model the impact of liquidation preferences, employee option pools, participating preferred (capped and uncapped), and more.

Discern if a startup’s financial forecasts are credible or closer to a fantasy novel.

Understand how “down rounds” and terms like anti-dilution and pay-to-play affect exits and investment results.

Value tech and biotech companies based on multiples and the DCF, with adjustments for “key person” risk, illiquidity, and more.

Explain how biotech and tech startups differ and how that translates into valuation, cap table, and exit differences.

Evaluate different deal structures, such as SAFE Notes vs. priced equity rounds, and the trade-offs between valuations

and downside protection for the investors.

Value biotech startups with a Sum-of-the-Parts DCF that analyzes each drug’s potential separately.

Build advanced cap tables with support for features such as convertible notes, venture debt, pro-rata equity, anti-dilution provisions,

participating preferred, and pari passu vs. ranked seniority.

Make investment recommendations based on everything above, factoring the qualitative and quantitative factors.